Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 6/20 | 0.48 |
| ▸ | BCR | P11274 | 6/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717797 | 0.86 | MEN1 (0.57) | RIPK1MEN1KMT2AMAPTABL1 | |
| SCHEMBL16254733 | 0.85 | ABL1 (0.66) | ABL1BCRBRAFLCKTEK | |
| SCHEMBL16254860 | 0.83 | ABL1 (0.56) | MEN1KMT2AMAPTABL1BCR | |
| SCHEMBL4717716 | 0.82 | LCK (0.67) | RIPK1MEN1KMT2AMAPTRET | |
| SCHEMBL16236903 | 0.79 | KDR (0.46) | ABL1BCRBRAF | |
| SCHEMBL16254767 | 0.79 | SRC (0.55) | ABL1BCRBRAF | |
| SCHEMBL16254743 | 0.79 | ABL1 (0.55) | RIPK1ABL1BCRBRAFLCK | |
| SCHEMBL4717158 | 0.77 | NLRP3 (0.56) | RIPK1MEN1KMT2AMAPTABL1 | |
| SCHEMBL16237017 | 0.76 | ABL1 (0.49) | ABL1BCRBRAFLCKTEK | |
| SCHEMBL16236489 | 0.76 | ABL1 (0.49) | MEN1KMT2AABL1BCRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | claimed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | claimed |
| EP-2997030-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-03-23 | — | — | EP | claimed |
| WO-2014184069-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-11-20 | — | — | WO | claimed |
| EP-2997030-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| EP-2997030-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | disclosed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | disclosed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | disclosed |
| EP-2997030-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014184069-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014184069-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | RET, DCK, PRKD2 | RIPK1 193/4885MEN1 3235/4885KMT2A 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.